Results 1 to 10 of about 61,025 (285)
Pulmonary Alveolar Proteinosis [PDF]
Canadian Respiratory Journal, 2012 Pulmonary alveolar proteinosis (PAP) is a disease of alveolar accumulation of phospholipoproteinaceous material that results in gas exchange impairment leading to dyspnea and alveolar infiltrates.
Sandeep M Patel +3 more
doaj +9 more sources
Pulmonary alveolar proteinosis [PDF]
European Respiratory Review, 2011 Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disease characterised by alveolar accumulation of surfactant. It may result from mutations in surfactant proteins or granulocyte macrophage-colony stimulating factor (GM-CSF) receptor genes, it may
B. Crestani +7 more
doaj +12 more sources
Primary pulmonary alveolar proteinosis [PDF]
Vojnosanitetski Pregled, 2012 Introduction. Pulmonary alveolar proteinosis is an uncommon disease characterized by the accumulation of surfactant proteins and phospholipids within the alveolar spaces. Acquired disease can be idiopathic (primary) and secondary.
Šarac Sanja +5 more
doaj +5 more sources
Pulmonary alveolar proteinosis [PDF]
Nature Reviews Disease Primers, 2019 Pulmonary alveolar proteinosis (PAP) is a syndrome characterized by the accumulation of alveolar surfactant and dysfunction of alveolar macrophages. PAP results in progressive dyspnoea of insidious onset, hypoxaemic respiratory failure, secondary infections and pulmonary fibrosis.
Bruce C Trapnell +2 more
exaly +10 more sources
Anaesthesia for serial whole-lung lavage in a patient with severe pulmonary alveolar proteinosis: a case report [PDF]
Journal of Medical Case Reports, 2008 Introduction Pulmonary alveolar proteinosis is a rare condition that requires treatment by whole-lung lavage. We report a case of severe pulmonary alveolar proteinosis and discuss a safe and effective strategy for the anaesthetic management of patients ...
Webb Stephen T +3 more
doaj +6 more sources
PULMONARY ALVEOLAR PROTEINOSIS
Annals of Internal Medicine, 1960 Excerpt Pulmonary alveolar proteinosis was first described by Rosen et al. in June, 1958.1We have had the opportunity to observe a patient with this disease, and wish to report the clinical, labora...
Leldon P. Pitt
+11 more sources
The Novel Use of Daratumumab in the Treatment of Refractory Autoimmune Pulmonary Alveolar Proteinosis. [PDF]
Respirol Case RepWe present a case of refractory autoimmune pulmonary alveolar proteinosis (aPAP) successfully treated with Daratumumab, a novel CD‐38 monoclonal antibody (mAb). ABSTRACT Autoimmune pulmonary alveolar proteinosis (aPAP) is caused by circulating anti‐granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) auto‐antibodies that impair alveolar macrophage
Strong A +4 more
europepmc +2 more sources
A New Era in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis. [PDF]
RespirologyRespirology, Volume 30, Issue 6, Page 463-465, June 2025.
Tazawa R, Nakata K.
europepmc +2 more sources
[Pulmonary alveolar proteinosis]. [PDF]
Pneumologie, 2002 Figure 1. A 26-year-old man presented with nonproductive cough and exertional dyspnea. Physical examination disclosed acrocyanosis. Chest radiography showed patchy alveolar and interstitial disease in a perihilar “batwing” distribution (Panel A). High-resolution computed tomography of the chest (Panel B) revealed extensive bilateral air-space disease ...
S. Jouneau +9 more
+8 more sources
Unsuspected pulmonary alveolar proteinosis in a patient with acquired immunodeficiency syndrome: a case report [PDF]
Journal of Medical Case Reports, 2011 Introduction Diffuse lung infiltrates are a common finding in patients with acquired immunodeficiency syndrome and causes range from infectious processes to malignancies or interstitial lung diseases.
Niazi Masooma +3 more
doaj +4 more sources